Compare Marvell Technology Inc (MRVL) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Twist Bioscience Corp — how do they compare? Marvell Technology Inc trades at $232.09 (market cap $200.91B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Marvell Technology Inc is far larger — about 23.9× Twist Bioscience Corp's market cap, and Marvell Technology Inc pays a 0.11% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| MRVL | TWST | |
|---|---|---|
Market Cap | $200.91B | $8.42B |
Sector | Technology | Health |
52-Week High | $316.43 | $153.10 |
52-Week Low | $66.59 | $24.16 |
Enterprise Value | $202.26B | $8.35B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $225.41, up 0.83% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth projections, with management forecasting $12 billion for fiscal 2026 and $18 billion for 2027. Despite negative net income in recent periods, the company has consistently beaten EPS expectations and maintains strong profitability margins. Technical indicators show bullish moving averages with support at $221 and resistance at $231.
Marvell presents significant growth potential driven by AI chip demand, with an 82% analyst buy rating and $303 consensus price target representing 34% upside. Key risks include intense competition from Broadcom, customer concentration, and high valuation multiples. The October Investor Day could serve as a catalyst for further price appreciation if growth projections are reaffirmed.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
